```html

Bacteraemia – A Comprehensive Medical Guide

Overview

Bacteraemia (also spelled “bacteremia”) is the presence of viable bacteria in the bloodstream. It can be transient, occurring after routine activities such as tooth brushing, or it can be persistent, leading to serious systemic infection. While anyone can develop bacteraemia, certain groups—particularly the elderly, immunocompromised patients, and those with invasive medical devices—are at higher risk.

Worldwide, bacteraemia is a common cause of hospital admission. In the United States, an estimated 250,000 to 500,000 cases of bloodstream infection (BSI) occur each year, accounting for up to 20 % of all hospital‑acquired infections and a mortality rate of 10‑30 % depending on the organism and patient factors (CDC, 2022; NIH, 2021).

Symptoms

Because bacteria in the blood can trigger a systemic inflammatory response, symptoms may mimic those of sepsis or other acute illnesses. Not every patient will have the same presentation, but common signs include:

• Fever or chills – sudden high temperature (>38 °C) with shaking.
• Rapid heart rate (tachycardia) – >100 beats/min.
• Increased respiratory rate (tachypnea) – >20 breaths/min.
• Low blood pressure (hypotension) – systolic <90 mmHg in adults.
• Generalized weakness or fatigue – often profound.
• Altered mental status – confusion, agitation, or decreased alertness.
• Skin changes – mottling, petechiae, or a rash (may suggest specific organisms like Neisseria meningitidis).
• Localized pain – joint or bone pain if the bacteria seed specific sites (e.g., osteomyelitis).
• Gastrointestinal symptoms – nausea, vomiting, or diarrhea, especially when the source is intra‑abdominal.
• Urinary symptoms – dysuria or flank pain if the urinary tract is the source.

Because these signs overlap with many conditions, laboratory testing is essential for confirmation.

Causes and Risk Factors

How bacteraemia develops

Bacteria can enter the bloodstream via:

1. Direct invasion – through a break in the skin (e.g., traumatic wound, intravenous catheter).
2. Hematogenous spread – from a primary infection such as pneumonia, urinary tract infection (UTI), or intra‑abdominal abscess.
3. Medical procedures – surgeries, endoscopy, dental work, or insertion of central lines.
4. Translocation from the gut – especially in patients with severe bowel disease or chemotherapy‑induced mucositis.

Key risk factors

• Advanced age (≥65 years)
• Immunosuppression (e.g., HIV, chemotherapy, steroids, organ transplant)
• Chronic illnesses – diabetes, chronic kidney disease, liver cirrhosis
• Presence of intravascular devices – central venous catheters, dialysis catheters, prosthetic heart valves
• Recent hospitalization or surgery
• Skin or soft‑tissue infections, especially cellulitis or abscesses
• Dental disease or recent dental procedures without prophylaxis in high‑risk patients

Diagnosis

Timely diagnosis hinges on a high index of suspicion and prompt laboratory work.

Blood cultures

• Quantity: Current guidelines recommend obtaining at least two sets of aerobic and anaerobic cultures from separate venipuncture sites before starting antibiotics.
• Timing: Ideally within the first hour of suspected sepsis; each set should be drawn ≥10 mL per bottle to maximize yield.
• Interpretation: Growth of the same organism in ≥2 bottles usually indicates true bacteraemia, while a single positive bottle may represent contamination (e.g., coagulase‑negative staphylococci).

Additional laboratory tests

• Complete blood count (CBC) – often reveals leukocytosis or leukopenia.
• Serum lactate – elevated >2 mmol/L suggests tissue hypoperfusion.
• Inflammatory markers – C‑reactive protein (CRP) and procalcitonin can help gauge severity.
• Renal and hepatic panels – assess organ function before initiating potentially nephrotoxic drugs.

Imaging & source identification

Once bacteraemia is confirmed, search for the primary source:

• Chest X‑ray or CT for respiratory sources.
• Abdominal ultrasound/CT for intra‑abdominal infections.
• Echocardiography (transthoracic or transesophageal) when endocarditis is suspected, especially with Staphylococcus aureus or viridans streptococci.

Treatment Options

Effective management combines antimicrobial therapy, source control, and supportive care.

Empiric antibiotic therapy

Start broad‑spectrum antibiotics within 1 hour of recognition, then de‑escalate based on culture results and susceptibility testing.

• Community‑onset, low risk: Ceftriaxone 2 g IV daily ± metronidazole if anaerobic coverage needed.
• Healthcare‑associated or high‑risk patients: Vancomycin (to cover MRSA) plus a β‑lactam with extended‑spectrum activity such as piperacillin‑tazobactam, cefepime, or carbapenem.
• For known Enterococcus or Pseudomonas infections, tailor to organism‑specific guidelines (e.g., ampicillin + ceftriaxone for Enterococcus faecalis).

Targeted therapy

After pathogen identification, narrow the regimen:

Organism	Preferred Agent(s)
Staphylococcus aureus (MSSA)	Oxacillin or cefazolin 2 g q8h
Staphylococcus aureus (MRSA)	Vancomycin (dose‑adjusted) or daptomycin
Escherichia coli (susceptible)	Ceftriaxone 2 g daily or cefotaxime
Enterococcus faecalis	Ampicillin + ceftriaxone or ampicillin + gentamicin
Streptococcus pneumoniae	Levofloxacin or high‑dose penicillin G

Duration of therapy

• Uncomplicated bacteraemia without a focus: 7‑10 days after the first negative blood culture.
• Endocarditis, osteomyelitis, or deep‑seated infections: 4‑6 weeks, often guided by infectious‑disease consultation.

Source control and procedures

• Removal of infected catheters or lines as soon as possible.
• Surgical drainage of abscesses, debridement of necrotic tissue, or valve replacement for endocarditis.
• Urinary catheter change or bladder drainage for UTIs.

Lifestyle and supportive measures

• Intravenous fluid resuscitation to maintain MAP ≥ 65 mmHg (sepsis guidelines).
• Oxygen supplementation or mechanical ventilation if respiratory failure develops.
• Analgesia, antipyretics, and nutritional support.

Living with Bacteraemia

Even after successful treatment, patients may need ongoing management to prevent recurrence.

• Medication adherence: Finish the full course of antibiotics, even if you feel better.
• Follow‑up labs: Repeat blood cultures if symptoms persist; monitor kidney and liver function during therapy.
• Device care: Keep central lines, PICC lines, and prosthetic devices clean; replace them according to physician schedule.
• Vaccinations: Stay up‑to‑date on influenza, pneumococcal (PCV20/PPV23), and COVID‑19 vaccines, which reduce risk of secondary infections.
• Hand hygiene: Wash hands with soap & water for at least 20 seconds; use alcohol‑based sanitizer when soap isn’t available.
• Healthy lifestyle: Balanced diet, regular moderate exercise, adequate sleep, and optimal control of chronic conditions (diabetes, hypertension).

Prevention

Many cases of bacteraemia are preventable with simple, evidence‑based practices.

1. Proper catheter management – Use aseptic technique, change dressings per protocol, and remove catheters as soon as they are no longer needed.
2. Peri‑operative antibiotic prophylaxis – Administer appropriate agents within 60 minutes before incision for surgeries that breach mucosal barriers.
3. Oral health – Regular dental cleanings; prophylactic antibiotics before dental work for patients with prosthetic heart valves or prior endocarditis (per AHA guidelines).
4. Vaccination – Influenza, pneumococcal, and hepatitis B vaccinations reduce bacterial seeding from respiratory or hepatic sources.
5. Control of chronic disease – Tight glycemic control (<7 % HbA1c) in diabetes lowers infection risk.
6. Prompt treatment of localized infections – Early antibiotics for skin cellulitis, UTIs, or pneumonia prevent bloodstream spread.

Complications

If bacteraemia is not identified and treated promptly, it can progress to life‑threatening complications:

• Sepsis and septic shock – Dysregulated host response leading to multiorgan failure.
• Infective endocarditis – Bacterial colonisation of heart valves; high morbidity.
• Metastatic infections – Abscesses in the brain, liver, spleen, joints, or bones.
• Acute respiratory distress syndrome (ARDS) – Severe pulmonary inflammation.
• Renal failure – Acute tubular necrosis from hypoperfusion or nephrotoxic antibiotics.
• Coagulopathy and disseminated intravascular coagulation (DIC) – Bleeding and clotting abnormalities.

Overall mortality for bloodstream infections remains 10‑30 % and rises sharply (>50 %) when septic shock develops (CDC, 2022).

When to Seek Emergency Care

---

Sources: Centers for Disease Control and Prevention (CDC). National Healthcare Safety Network (NHSN) Antimicrobial Resistance and Utilization (ARU) Reports, 2022; National Institutes of Health (NIH). Sepsis and Bacteremia Clinical Guidelines, 2021; Mayo Clinic. Bacteremia: Symptoms and Treatment, 2023; Cleveland Clinic. Bloodstream Infections, 2022; World Health Organization (WHO). Antimicrobial Resistance Fact Sheet, 2023.

```